31 March 2015
Researchers at the University of Washington in the US have signed an exclusive agreement with Avalanche Biotechnologies to develop gene-therapy treatments for colour vision deficiency (CVD).
The exclusive licensing deal will see researchers develop Avalanche’s Ocular Biofactory technology to treat red-green colour blindness.
The work will expand on previous research which used gene therapy to restore colour vision in primates with CVD.
“Avalanche is performing pioneering research that has the potential to cure CVD,” said Jay Neitz, Professor of Ophthalmology at the University of Washington. He added: “CVD is just one of the many diseases that could be treated with Avalanche’s technology.”
As part of the agreement, Avalanche has also launched a disease awareness website.
The exclusive licensing deal will see researchers develop Avalanche’s Ocular Biofactory technology to treat red-green colour blindness.
The work will expand on previous research which used gene therapy to restore colour vision in primates with CVD.
“Avalanche is performing pioneering research that has the potential to cure CVD,” said Jay Neitz, Professor of Ophthalmology at the University of Washington. He added: “CVD is just one of the many diseases that could be treated with Avalanche’s technology.”
As part of the agreement, Avalanche has also launched a disease awareness website.
Comments (0)
You must be logged in to join the discussion. Log in